| Literature DB >> 34376183 |
Shuai-Shuai Shi1, Xian-Zu Yang2, Xiao-Ye Zhang2, Hui-Dan Guo1, Wen-Feng Wang3, Li Zhang1, Peng Wu4, Wei Zhang1, Wen-Bin Wen1, Xiao-Lei Huo5, Yi-Qiang Zhang6.
Abstract
BACKGROUND: Horseshoe kidney (HSK) is a common congenital defect of the urinary system. The most common complications are urinary tract infection, urinary stones, and hydronephrosis. HSK can be combined with glomerular diseases, but the diagnosis rate of renal biopsy is low due to structural abnormalities. There are only a few reports on HSK with glomerular disease. Here, we have reported a case of PLA2R-positive membranous nephropathy occurring in a patient with HSK. CASEEntities:
Keywords: Horseshoe kidney; Membranous nephropathy; Nephritic syndrome; PLA2R positive
Mesh:
Substances:
Year: 2021 PMID: 34376183 PMCID: PMC8353813 DOI: 10.1186/s12882-021-02488-7
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1B-mode ultrasonography. A The ultrasound probe is placed on the midline of the upper abdomen of the umbilical cord. B The ultrasound probe is placed on the right abdomen. C The ultrasound probe is placed on the left abdomen
Fig. 2A Light micrograph (PASM stain, ×400): The arrow shows basement membrane thickening, nail structure formation; B Immunofluorescent stain (× 200): immunoglobulin G4 deposition (3+) in fine granular deposits along the capillary loops. C Immunofluorescent stain (× 200): PLA2R (+). (D) Electron microscope (× 3000): The arrow shows the electron dense substance was deposited in the subepithelial and basement membranes of glomerular capillary loops, some spikes
Domestic and foreign case reports of patients with horseshoe kidney with glomerular disease
| Pathological type of renal biopsy | Age (year) | Sex | Therapeutic regimen | Effect of treatment | |
|---|---|---|---|---|---|
| MN | 20 | Male | Prednisolone | Remission | 1990 [ |
| 48 | Female | – | – | 1992 [ | |
| 18 | Female | MP + ACEI | Remission | 2001 [ | |
| – | – | MP + LEF | Remission | 2014 | |
| FSGS | 52 | Male | CSA | Remission | 1991 [ |
| 23 | Male | – | 2007 [ | ||
| Male | Failure to tolerate therapy | Worsen | 2010 [ | ||
| – | – | MP | Control | 2014 | |
| IgAN | 26 | Male | ACEI | Remission | 2014 [ |
| – | – | ACEI | Remission | 2014 | |
| MCD | 22 | Male | Prednisone | CR | 2016 [ |
| 64 | Female | MP | Remission | 2018 | |
| MSPGN | 8 | Female | Prednisolone + CTX | Remission | 2003 |
| MPGN | 38 | Male | Prednisone + CTX | Remission | 1996 |
| Renal amyloidosis | Male | – | – | 2007 [ | |
| HSPN | 15 | Female | MP + LEF | Remission | 2014 |
| MP + LEF | CR | 2014 | |||
| LN | MP + MMF | Control | 2014 | ||
| The patient refused (LN) | 35 | Female | Prednisone + CTX | Remission | 2010 |
| No biopsy | 27 | Female | Prednisone | CR | 2016 |
MP Methylprednisolone, LEF Leflunomide, CTX Cyclophosphamide, MMF Mycophenolate mofetil, CR Complete remission